<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996914</url>
  </required_header>
  <id_info>
    <org_study_id>20-341</org_study_id>
    <nct_id>NCT04996914</nct_id>
  </id_info>
  <brief_title>Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma</brief_title>
  <acronym>ASTrH</acronym>
  <official_title>Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC&#xD;
      not amenable for surgical resection or orthotopic liver transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year local control rate</measure>
    <time_frame>12 Months</time_frame>
    <description>After one year from the treatment, the precentage with alive subjects with no signs of local progression (the irradiated lesion).&#xD;
Local progression defined as more than 20% increase in diameter of enhancing tumor on contrast-enhanced CT scan in arterial phase or a new tumor mass within the original tumor volume according to modified RECIST criteria (mRECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualtiy of life based on EORTC QLQC30</measure>
    <time_frame>12 Months</time_frame>
    <description>alive subjects will fill quality of life questionnaires (EORTC QLQC30) before the treatment and after 3,6 and 12 months after.&#xD;
The results before and after the treatment will be presented in comaprsion to the reference data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1- year progression free survival</measure>
    <time_frame>12 Months</time_frame>
    <description>After one year from the end of the treatment, the percentage of alive subjects without the apperance of new hepatic and/or extra-heaptic new lesions outside the SBRT-field.&#xD;
This will be measured using contrast-enhanced CT scan Liver/Abdomen and Thorax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life based on EORTC QLQ-HCC18</measure>
    <time_frame>12 Months</time_frame>
    <description>alive subjects will fill quality of life questionnaires (EORTC QLQ-HCC18) before the treatment and after 3,6 and 12 months after.&#xD;
The results before and after the treatment will be presented in comaprsion to the reference data.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>TACE+SBRT.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient is eligible to participate in the project according to the in- and exclusion criteria, the patient will assigned to 1-2 sessions of TACE followed by SBRT within one month from last TACE session .</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>1-2 session TACE before SBRT according to the preference of the interventional radiologist. Goal of TACE is the complete emnbolization of the HCC-nodules. It is allowed to use both conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) according to the interventional radiologist preference.</description>
    <arm_group_label>TACE+SBRT.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT should be 1 month after last TACE. This can be extended till 2 months if indicated. However, prolongation of the gap between TACE and SBRT is not encouraged.&#xD;
Treatment center should choose one of fractionation schedule mentioned allowed in the study, in order to achieve a balance between dose applied for tumor control and constraints for OAR PTV Dose in 5 / 8 fractions (Gy) BED (α/β 10Gy) 5x 10 Gy @ 83% isodose = 50 Gy (100 Gy) 8 x 7.5 Gy @ 83% isodose = 60 Gy (105 Gy)</description>
    <arm_group_label>TACE+SBRT.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HCC (diagnosis: histological or radiological)&#xD;
&#xD;
          -  Age: 18-80&#xD;
&#xD;
          -  Number of lesions 1-3 lesions&#xD;
&#xD;
          -  Size of the lesion (or sum of 2-3 lesions) ≥ 4 cm&#xD;
&#xD;
          -  Sufficient non-tumorous liver volume (≥ 800 cm3)&#xD;
&#xD;
          -  Child Pugh Score: A5-6 or B7&#xD;
&#xD;
          -  BCLC A or B&#xD;
&#xD;
          -  Patient is illegible or refused surgical resection or orthotopic liver transplant&#xD;
&#xD;
          -  Blood work (within 2 weeks before registration):&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³)&#xD;
&#xD;
          -  Platelets ≥50,000 cells/mm³&#xD;
&#xD;
          -  AST (and ALT) &lt; 5 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ ULN or creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of extrahepatic disease (lymph node or distant metastases)&#xD;
&#xD;
          -  Evidence of macroscopic vascular invasion&#xD;
&#xD;
          -  Evidence of an arterio-portal or arterio-venous fistulas&#xD;
&#xD;
          -  History of previous malignancy&#xD;
&#xD;
          -  Active hepatitis B&#xD;
&#xD;
          -  Previous SIRT&#xD;
&#xD;
          -  Previous Sorafenib in the last 8 weeks&#xD;
&#xD;
          -  Pregnant and lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Eble, Professor Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University medical center RWTH Aachen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp Bruners, Professor Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University medical center RWTH Aachen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Allam Mohamed, MBBS, MSc, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University medical center RWTH Aachen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Allam Mohamed, MBBS,MSc, MD</last_name>
    <phone>8036866</phone>
    <phone_ext>+49-241</phone_ext>
    <email>amohamed@ukaachen.de</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

